The European Commission said on Tuesday it has signed a joint purchase contract with Spanish pharmaceutical company HIPRA for the supply of its COVID-19 vaccine, which will be available if approved by the European Medicines Agency.
The European Commission said in a statement that 14 countries participate in the agreement, under which they can purchase up to 250 million doses.
HIPRA expects its vaccine, which is subject to a continuous review process by the EMA, to be approved and ready to be administered in the autumn, the Spanish company said in a statement, calling the EU announcement a “sign of confidence”. ” on your vaccine.
“With the increase in COVID-19 infections in Europe, we have to ensure maximum preparation for the autumn and winter months,” European Commissioner for Health Stella Kyriakides said in the statement.
“HIPRA’s vaccine adds one more option to complement our extensive portfolio of vaccines for our member states and citizens,” he said, adding that increased vaccination and booster vaccination would be essential in the coming months.
The HIPRA bivalent recombinant protein vaccine, which is currently under continuous review by the EMA, is being developed as a booster dose in previously immunized people aged 16 years and older. It uses a recombinant protein like that of the American Novavax.
A senior HIPRA official told Reuters in December that he was confident there would be demand in the EU for its experimental COVID-19 vaccine as it is designed to protect against new variants, can be easily transported at low temperatures and produced in mass quantities. .
HIPRA, a company that has specialized in veterinary vaccines for some 50 years and operates in more than 100 countries, had already closed a purchase agreement for 50 million doses with Vietnam, where it carried out tests.